Biocon Biologics launches Nepexto, its Enbrel biosimilar, in Australia with partner Generic Health to expand autoimmune treatment access.

• Nepexto treats autoimmune diseases like rheumatoid arthritis and psoriasis by inhibiting tumor necrosis factor (TNF).
• The product has already been widely adopted in Europe since EU approval in 2020, following Biocon's biosimilars expansion.
• Launch strengthens Biocon's global immunology portfolio and supports strategic market growth beyond Europe.